COGT
NASDAQ HealthcareCogent Biosciences, Inc. - Common Stock
Biotechnology
Cogent Biosciences, Inc., a clinical-stage biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor in Phase 3 trial designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company also develops CGT4859, a reversible and selective fibroblast growth factor receptor 2 inhibitor in Phase 1 trial for patients with documented FGFR mutations, including advanced cholangiocarcinoma; CGT4255, a novel ErbB2 mutant program, which is focused on actionable and underserved mutations in a solid tumor systemic and CNS involved indications; and CGT6297, a Novel PI3Ka mutant-selective inhibitor. It has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. Cogent Biosciences, Inc. is headquartered in Waltham, Massachusetts.
�� 市场数据
| 价格 | $37.25 |
|---|---|
| 成交量 | 3,869,493 |
| 市值 | 6.05B |
| 贝塔系数 | 0.470 |
| RSI（14日） | 54.9 |
| 200日均线 | $26.19 |
| 50日均线 | $36.68 |
| 52周最高 | $43.73 |
| 52周最低 | $4.20 |
| Forward P/E | -54.08 |
| Price / Book | 10.97 |
🎯 投资策略评分
COGT 在各投资策略中的评分。分数越高，越符合该策略目标。
🔍 策略解读
最佳匹配： 🐋 Institutional Whale (64/100) — 此策略 大盘、机构级别股票.
评分最低的策略： 🎈 Over-Hyped (15/100). 单一评分不构成买入或卖出信号 — 请结合多种视角综合判断。 了解如何解读这些评分 →
📚 了解更多
在文本中查找 COGT in your text
粘贴任何文章、记录或帖子 — 工具将提取 COGT 以及每一个其他隐藏的股票代码。
免责声明：本数据仅供教育和娱乐用途，不构成金融建议。市场数据可能存在延迟。在做出投资决策之前，请始终进行自己的研究。
数据最后更新： 2026-04-17.